G

Geron Corp
D

GERN

3.33500
USD
-0.18
(-4.99%)
مغلق
حجم التداول
569,150
الربح لكل سهم
-0
العائد الربحي
-
P/E
-10
حجم السوق
2,016,010,888
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CRSP
    -0.220
    (-0.54%)
    40.500 USD
    JNJ
    JNJ
    0.780
    (0.54%)
    145.230 USD
    MRK
    MRK
    1.210
    (1.23%)
    99.360 USD
    PFE
    PFE
    0.350
    (1.33%)
    26.710 USD
    T
    TK
    0.29000
    (4.59%)
    6.61000 USD
    V
    VSTM
    -0.23000
    (-5.48%)
    3.97000 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    XOM
    XOM
    0.410
    (0.39%)
    106.280 USD
    المزيد
الأخبار
المقالات

العنوان: Geron Corp

القطاع: Healthcare
الصناعة: Biotechnology
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.